Novo Nordisk A/S vs Old Dominion Freight Line Inc — how do they compare? Novo Nordisk A/S trades at $44.99 (market cap $200.69B), while Old Dominion Freight Line Inc trades at $182.25 (market cap $38.77B). The key difference: Novo Nordisk A/S is far larger — about 5.2× Old Dominion Freight Line Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | ODFL | |
|---|---|---|
Market Cap | $200.69B | $38.77B |
Sector | Health | Industrials |
52-Week High | $63.98 | $248.73 |
52-Week Low | $35.29 | $126.29 |
Enterprise Value | $215.49B | $38.51B |
Dividend Yield | 3.98% | 0.62% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
ODFL trades at $187.01, up 0.61% on the day, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. Recent news highlights institutional buying and sustainability reporting, while August LTL revenue per day rose 12.4% year-over-year (Business Wire, 2026-09-03).
The outlook is mixed: high valuation ratios (P/E 35.96) and declining revenue trends pose risks, but analyst consensus targets $238.73 with a buy rating from 36% of coverage. Upside hinges on freight recovery and cost discipline, while competition and economic sensitivity are key concerns.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →